CD274 and cancer: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, one of the most common immunotherapies, have gained increasing attention for their value in oncology treatment and provide a paradigm to revolutionize the translation of cancer immunotherapy from the laboratory to the clinic (20–24).